Anatoly Reder: “The development of original drugs – our competitive advantage”

One of the priorities of the company “InterChem” is scientific research. On the basis of its own laboratory, equipped in accordance with international standards, innovative medicines is being developed, as well as the provision and control of product quality at every stage of production. In 2005, for the first time in the pharmaceutical industry in Eastern Europe “InterHim” created an independent laboratory equipped for the development of compounds and technologies for the production of solid dosage forms and for production under GMP conditions for a bioseries of pre-clinical and clinical trials of medicines.

About the difficulties and benefits of work of innovative enterprise magazine “Pharmaceutical Courier” told Anatoly Reder, CEO of “InterChem”, Ph.D., Honored Worker of pharmaceutical industry of Ukraine, winner the award of the National Academy of Sciences of Ukraine named after Academician Kiprianov.

Ph.C.: Anatoly, original products make up a significant share of the portfolio of your company, which is not typical for Ukrainian producers. Are develop molecule from scratch is more profitable than copy and withdraw a popular drug on the Ukrainian market? 

A.R.: When “InterHim” began its work (it was in the early 90 – ies), we actually knew very little about the pharmaceutical industry, however, we understood that such a development of new molecules. At first we just found their biological properties, gradually learned to explore them, and then – create medicines and promote our own elaborations in the market. Of course, as the beginners on the pharmaceutical market of finished drugs at that stage we could not compete with experienced players. So, in fact, we have chosen our way – to develop new molecules, the original drugs. And it has become our competitive advantage we successfully use until now. Although throughout the world to bring to market a new molecule – an extremely difficult and very expensive task.

Ph.C.: But to invent a molecule – that’s not all …

A.R.: Yes, of course, further is the turn of the other stages, long and difficult. But top notch – this is to develop a new molecule, to prove that it has a right to exist, and then create on its basis medication, register it, and bring to market. Of course, a major achievement is the development of the technology of the dosage form with the already known or unknown molecule. After all, the production of one form or another may significantly change the properties of the finished product. In this sense, it is extremely important for us that we have a very powerful and competitive tool – Science and Technology Laboratory “FormulaB” created in collaboration with well-known German company Meggle GmbH. This laboratory allows us to feel confident in the development of technologies of the ready solid dosage forms. Today, thanks to this tool, we are able to quickly and easily create quite complex pharmaceutical forms, such as modified release tablets, multi-layer coatings, sublingual tablets, and much more. This is an extremely high-end technologies, which not everyone is able to master on their own now.

Read the full interview in the September issue of the magazine “Pharmaceutical Courier”